• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail
-

Percentage of NDI notification reviews completed to which FDA objected

Dictionary: Timely review of notifications of new dietary ingredients impacts the public health by preventing substances that are not actually dietary ingredients from being used in dietary supplements, and assuring that new dietary ingredients have adequate evidence for presumption of safety. Since these statutory requirements are notifications rather than pre-market approvals, it is essential that the Office of Dietary Supplement Programs (ODSP) has completed review of the information before the submitter markets the product to notify them of any safety or regulatory concerns before the product reaches consumers.

Information is current as of March 31, 2020.

Fiscal Year - 2020

Skip graphic and jump to text data

TimeTargetPercentage
Oct 2019N/A100
Nov 2019N/A67
Dec 2019N/A100
Jan 2020N/A0
Feb 2020N/A75
Mar 2020N/A100
Apr 2020N/ATBD
May 2020N/ATBD
Jun 2020N/ATBD
Jul 2020N/ATBD
Aug 2020N/ATBD
Sep 2020N/ATBD

FY 2020 YTD: 74%

Footnotes

  • During the government shutdown (furlough) from December 22, 2018 through January 25, 2019, the majority of CFSAN employees were on furlough status, which directly impacted the FY 2019 Q2 data for various food safety programs. Because the furloughed staff were not permitted to work, CFSAN’s ability to accomplish many performance targets, including conducting timely reviews of industry submissions received during the shutdown were either delayed, deferred to the next reporting cycle, or, not met.

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.

-
-